Stay updated with breaking news from Gregoryj Zipfel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Egret Therapeutics, a clinical-stage company focused on the treatment of neurological diseases, today announced the expansion of its Scientific...
/PRNewswire/ -- Egret Therapeutics, a clinical-stage company focused on the treatment of neurological diseases, today announced the expansion of its Scientific...
Press Release Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis and Barnes-Jewish Hospital have established the Brain Tumor Center, a multidisciplinary practice of physicians and scientists whose mission is to provide leading-edge, patient-centric care for brain tumor patients while also developing transformative basic, translational and clinical research to develop new therapies and improve patient outcomes. Neurosurgeon and scientist Albert H. Kim, MD, PhD, has been appointed inaugural director of the center, which is based at ...
In mice, antibody removes amyloid, improves vessel function without raising risk of brain bleeds Amyloid deposits (blue) in mouse brain tissue and blood vessels are reduced after treatment with an antibody that targets the protein APOE (right), a minor component of amyloid deposits, compared to a placebo antibody (left). Amyloid deposits in the brain increase the risk of dementia and strokes. Researchers at Washington University School of Medicine in St. Louis have identified an antibody that clears amyloid deposits from the brain without raising the risk of brain bleeds. (Image: Monica Xiong...
Researchers identify antibody that removes amyloid plaques without the risk of brain bleeds As people age, a normal brain protein known as amyloid beta often starts to collect into harmful amyloid plaques in the brain. Such plaques can be the first step on the path to Alzheimer's dementia. When they form around blood vessels in the brain, a condition known as cerebral amyloid angiopathy, the plaques also raise the risk of strokes. Several antibodies that target amyloid plaques have been studied as experimental treatments for Alzheimer's disease. Such antibodies also may have the potential to ...